Avalyn Pharma Inc. (NASDAQ:AVLN – Get Free Report) shares shot up 7.4% on Friday . The stock traded as high as $28.99 and last traded at $28.99. 8,364 shares were traded during trading, a decline of 97% from the average session volume of 318,232 shares. The stock had previously closed at $26.99.
Analyst Upgrades and Downgrades
Several brokerages recently weighed in on AVLN. Morgan Stanley began coverage on shares of Avalyn Pharma in a research report on Tuesday, May 26th. They set an “overweight” rating and a $53.00 price objective on the stock. Zacks Research upgraded Avalyn Pharma to a “hold” rating in a report on Wednesday, May 27th. Wall Street Zen upgraded Avalyn Pharma to a “hold” rating in a report on Saturday, May 9th. Jefferies Financial Group initiated coverage on Avalyn Pharma in a report on Monday, May 25th. They set a “buy” rating and a $52.00 price target on the stock. Finally, Guggenheim initiated coverage on Avalyn Pharma in a report on Monday, May 25th. They set a “buy” rating and a $80.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, Avalyn Pharma has an average rating of “Buy” and an average target price of $59.00.
View Our Latest Research Report on AVLN
Avalyn Pharma Trading Up 4.7%
Insider Buying and Selling at Avalyn Pharma
In related news, Director Jill Carroll acquired 277,778 shares of the stock in a transaction dated Friday, May 1st. The shares were acquired at an average price of $18.00 per share, for a total transaction of $5,000,004.00. Following the completion of the purchase, the director owned 2,186,562 shares in the company, valued at approximately $39,358,116. The trade was a 14.55% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Sr One Capital Management, Llc acquired 555,555 shares of the stock in a transaction dated Friday, May 1st. The stock was bought at an average price of $18.00 per share, for a total transaction of $9,999,990.00. Following the purchase, the insider owned 2,186,562 shares of the company’s stock, valued at $39,358,116. The trade was a 34.06% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.
About Avalyn Pharma
We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.
Featured Articles
- Five stocks we like better than Avalyn Pharma
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
- NVIDIA’s New Power Play: Why Fluence Is Surging
- Broadcom’s Whiplash: Shares Tank After Pre-Earnings Surge
Receive News & Ratings for Avalyn Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalyn Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
